A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)
Phase of Trial: Phase III
Latest Information Update: 05 Jan 2017
At a glance
- Drugs Diazepam (Primary)
- Indications Seizures
- Focus Adverse reactions; Registrational
- Sponsors Neurelis
- 05 Jan 2017 According to a Neurelis media release, company plans for New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in 2018.
- 30 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 21 Jan 2016 New trial record